Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized

Philip D Harvey1, Michael F Green, Susan R McGurk

  • 1Department of Psychiatry, Mt. Sinai School of Medicine, Box 1229, New York, NY 10029, USA. pdharvey@compuserve.com

Psychopharmacology
|February 19, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of 5-HT7 receptor gene deletion on memory and affective behaviors in young and aged mice.

Neuroscience·2025
Same author

Role of serotonin 5HT 2C receptors in the discriminative stimulus properties of lorcaserin in male C57BL/6 mice.

Behavioural pharmacology·2025
Same author

Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.

The lancet. Psychiatry·2025
Same author

Genetic markers of early response to lurasidone in acute schizophrenia.

The pharmacogenomics journal·2025
Same author

Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder.

Journal of clinical psychopharmacology·2024
Same author

Analysis of schizophrenia-associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Human psychopharmacology·2024

Risperidone and olanzapine equally improved cognitive functioning in schizophrenia patients. These atypical antipsychotics offer broad cognitive benefits, not solely due to symptom or movement improvements.

Area of Science:

  • Psychiatry and Neuroscience
  • Pharmacology

Background:

  • Schizophrenia is a complex psychiatric disorder characterized by cognitive deficits.
  • Atypical antipsychotics like risperidone and olanzapine are primary treatments, but their comparative effects on cognition require clarification.

Purpose of the Study:

  • To compare the efficacy of risperidone and olanzapine in improving cognitive functioning in patients with schizophrenia.
  • To investigate whether observed cognitive improvements are directly attributable to the medications or secondary to clinical symptom changes.

Main Methods:

  • A randomized, double-blind trial involving 377 schizophrenia patients.
  • Patients received either risperidone (2-6 mg/day) or olanzapine (5-20 mg/day) for 8 weeks.
  • Cognitive function was assessed using a battery of tests, alongside evaluations for extrapyramidal symptoms (ESRS) and overall psychopathology (PANSS).

Related Experiment Videos

Main Results:

  • Both risperidone and olanzapine significantly improved performance across multiple cognitive domains, including executive function, memory, and attention.
  • No significant differences were found between risperidone and olanzapine in their effects on cognitive performance.
  • Adjusting for anticholinergic treatment did not alter the observed cognitive benefits.

Conclusions:

  • Atypical antipsychotic treatment with risperidone or olanzapine provides substantial, wide-ranging benefits for cognitive deficits in schizophrenia.
  • The study did not support previous claims of superior cognitive benefits of olanzapine over risperidone.
  • Cognitive improvements appear to be a direct effect of these medications, independent of changes in clinical symptoms or motor side effects.